Sermorelin Research Peptide

Sermorelin is a synthetic research peptide corresponding to the first 29 amino acids of native growth hormone–releasing hormone (GHRH 1–44), a region recognized as the peptide's primary biologically active sequence. In experimental settings, Sermorelin interacts with GHRH receptors located on pituitary somatotroph cells and initiates intracellular signaling through adenylate cyclase activation and cAMP-dependent pathways. Preclinical studies commonly employ Sermorelin to examine mechanisms of growth hormone synthesis and secretion, as well as regulatory processes within the hypothalamic–pituitary axis. Its defined structure and receptor specificity make it a useful research tool for investigating endocrine feedback loops, somatotropic signaling pathways, and peptide-mediated regulation of pituitary function under controlled laboratory conditions.

Evidence classification: Sermorelin was historically studied clinically in a pharmaceutical formulation; that evidence does not apply to research-grade material. Much mechanistic research is in vitro and animal.